Geographic differences in approach to advanced gastric cancer: Is there a standard approach?

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 416-426

  Kim, Richard ^a   Tan, Ann ^b   Choi, Minsig ^c   El Rayes, Bassel F ^d  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c KARMANOS CANCER INSTITUTE   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Advanced gastric cancer; Biomarkers; Chemotherapy; Regional differences

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; EVEROLIMUS; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN; NEUROPILIN; OXALIPLATIN; PACLITAXEL; PLACEBO; RAMUCIRUMAB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULOTROPIN A;

ADVANCED CANCER; ADVANCED GASTRIC CANCER; ANEMIA; ANOREXIA; ASIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COLON CANCER; DIARRHEA; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GEOGRAPHIC DISTRIBUTION; HAND FOOT SYNDROME; HUMAN; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH CANCER; STOMACH SURGERY; TREATMENT OUTCOME; UNITED STATES;

ADVANCED GASTRIC CANCER; BIOMARKERS; CHEMOTHERAPY; REGIONAL DIFFERENCES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; BIOLOGICAL MARKERS; DEVELOPED COUNTRIES; GEOGRAPHY, MEDICAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84885836475     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.007     Document Type: Review

References (71)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
2. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2010, CD004064.
3. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine 2008, 358:36-46.
4. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. Journal of Clinical Oncology 2006, 24:4991-4997.
5. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology 1997, 15:261-267.
6. Kang J.H., Lee S.I., Lim do H., et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology 2012, 30:1513-1518.
7. Schwarz R.E., Zagala-Nevarez K. Ethnic survival differences after gastrectomy for gastric cancer are better explained by factors specific for disease location and individual patient comorbidity. European Journal of Surgical Oncology 2002, 28:214-219.
8. Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of Clinical Oncology 2011, 29:4387-4393.
9. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006, 355:11-20.
10. Noguchi Y., Yoshikawa T., Tsuburaya A., Motohashi H., Karpeh M.S., Brennan M.F. Is gastric carcinoma different between Japan and the United States?. Cancer 2000, 89:2237-2246.
11. Kattan M.W., Karpeh M.S., Mazumdar M., Brennan M.F. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. Journal of Clinical Oncology 2003, 21:3647-3650.
12. Strong V.E., Song K.Y., Park C.H., et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Annals of Surgery 2010, 251:640-646.
13. Japanese Gastric Cancer A Japanese gastric cancer treatment guidelines 2010 (ver 3). Gastric Cancer 2011, 14:113-123.
14. Bonenkamp J.J., Hermans J., Sasako M., et al. Extended lymph-node dissection for gastric cancer. New England Journal of Medicine 1999, 340:908-914.
15. Songun I., Putter H., Kranenbarg E.M., Sasako M., van de Velde C.J. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology 2010, 11:439-449.
16. Boku N., Yamamoto S., Fukuda H., et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology 2009, 10:1063-1069.
17. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology 2008, 9:215-221.
18. Fujii M., Satoh T., Kim Y.H., et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update. Journal of Clinical Oncology 2011, 29. [suppl; Abstract 4016].
19. Koizumi W., Nakayama N., Tanabe S., et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemotherapy and Pharmacology 2012, 69:407-413.
20. Koizumi W., Takiuchi H., Yamada Y., et al. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Annals of Oncology 2010, 21:1001-1005.
21. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. Journal of Clinical Oncology 2006, 24:2903-2909.
22. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology 2002, 20:1996-2004.
23. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology 2008, 26:1435-1442.
24. Okines A., Verheij M., Allum W., Cunningham D., Cervantes A. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010, 21(Suppl. 5):v50-v54.
25. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007, 25:3205-3209.
26. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007, 25:3210-3216.
27. Shah M., Stoller R., Shibata S., et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). Journal of Clinical Oncology 2010, 28(15s). [suppl; Abstract 4014].
28. Al-Batran S.E., Hartmann J.T., Hofheinz R., et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of Oncology 2008, 19:1882-1887.
29. Ajani J.A., Rodriguez W., Bodoky G., et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology 2010, 28:1547-1553.
30. Gadgeel S.M., Shields A.F., Heilbrun L.K., et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. American Journal of Clinical Oncology 2003, 26:37-41.
31. Lee J., Kang W.K., Kwon J.M., et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Annals of Oncology 2007, 18:88-92.
32. Cao W.G., Yang W.P., Lou G.Y., et al. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anti-Cancer Drugs 2009, 20:287-293.
33. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
34. Haller D.G., Cassidy J., Clarke S.J., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. Journal of Clinical Oncology 2008, 26:2118-2123.
35. Lewis C.J., Crane N.T., Wilson D.B., Yetley E.A. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. The American Journal of Clinical Nutrition 1999, 70:198-207.
36. Ajani J.A., Faust J., Ikeda K., et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. Journal of Clinical Oncology 2005, 23:6957-6965.
37. Chau I., Norman A., Ross P. Multivariate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer - pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. ASCO gastrointestinal cancers symposium 2004, [Abstract 5].
38. Catalano V., Graziano F., Santini D., et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?. British Journal of Cancer 2008, 99:1402-1407.
39. Lee J., Lim T., Uhm J.E., et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Annals of Oncology 2007, 18:886-891.
40. Wesolowski R., Lee C., Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncology 2009, 10:903-912.
41. Thuss-Patience P.C., Kretzschmar A., Bichev D., et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer 2011, 47:2306-2314.
42. Cappetta A., Lonardi S., Pastorelli D., Bergamo F., Lombardi G., Zagonel V. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Critical Reviews in Oncology/Hematology 2012, 81:38-48.
43. Ueda S., Yasui H.S., Nishina H., et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. Journal of Clinical Oncology 2012, 30. [suppl; Abstract 4002].
44. Chun J.H., Kim H.K., Lee J.S., et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Japanese Journal of Clinical Oncology 2004, 34:8-13.
45. Lee J.L., Ryu M.H., Chang H.M., et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemotherapy and Pharmacology 2008, 61:631-637.
46. Kodera Y., Ito S., Mochizuki Y., et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Research 2007, 27:2667-2671.
47. Kim S.G., Oh S.Y., Kwon H.C., et al. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Japanese Journal of Clinical Oncology 2007, 37:744-749.
48. Kim D.Y., Kim J.H., Lee S.H., et al. study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Annals of Oncology 2003, 14:383-387.
49. Takiuchi H. Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials. Gastric Cancer 2011, 14:206-211.
50. Assersohn L., Brown G., Cunningham D., et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Annals of Oncology 2004, 15:64-69.
51. Ohtsu A., Shah M.A., Van Cutsem E., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2011, 29:3968-3976.
52. Guimbaud R., Louvet C., Bonnetain F., et al. Final results of the intergroup FFCD-GERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers. Annals of Oncology 2010, 21:250-260.
53. Gubanski M., Johnsson A., Fernebro E., et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010, 13:155-161.
54. Yin M., Yan J.R., Martinez-Balibrea E., et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clinical Cancer Research 2011, 17:1632-1640.
55. Yeh K.H., Shun C.T., Chen C.L., et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998, 82:1626-1631.
56. Fukuda H., Takiguchi N., Koda K., Oda K., Seike K., Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Investigation 2006, 24:235-241.
57. Koizumi W., Tanabe S., Azuma M., et al. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. International Journal of Cancer Journal International du Cancer 2010, 126:162-170.
58. Tan I.B., Ivanova T., Lim K.H., Ong C.W., Deng N., Lee J., et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011, 141:476-485. 85 e1-e11.
59. Van Cutsem E., de Haas S., Kang Y.K., et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. Journal of Clinical Oncology 2012, 30:2119-2127.
60. Waddell T.S., Chau I., Barbachano Y., et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). Journal of Clinical Oncology 2012, 39. [suppl; Abstract LBA4000].
61. Kim Y., Sasaki Y., Lee K., et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil-based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: preliminary results. Journal of Clinical Oncology 2011, 29(suppl 4). [Abstract 87].
62. Yoon D.H., Ryu M.H., Park Y.S., et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. British Journal of Cancer 2012, 106:1039-1044.
63. Shah M.A., Khanin R., Tang L., et al. Molecular classification of gastric cancer: a new paradigm. Clinical Cancer Research 2011, 17:2693-2701.
64. Tay S.T., Leong S.H., Yu K., et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. Cancer Research 2003, 63:3309-3316.
65. Fujii M., Satoh K.H.H. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update, 2011 ASCO Annual Meeting. Journal of Clinical Oncology 2011, 29. [suppl; Abstract 4016].
66. Kornek G.V., Raderer M., Schull B., et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and or erythropoletin in patients with advanced gastric cancer. British Journal of Cancer 2002, 86:1858-1863.
67. Dank M., Zaluski J., Barone C., et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology 2008, 19:1450-1457.
68. Bouche O., Raoul J.L., Bonnetain F., et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. Journal of Clinical Oncology 2004, 22:4319-4328.
69. Cascinu S., Graziano F., Cardarelli N., et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs 1998, 9:307-310.
70. Jeung H.C., Rha S.Y., Shin S.J., et al. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. British Journal of Cancer 2007, 97:458-463.
71. Park S.H., Kang W.K., Lee H.R., et al. Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen. American Journal of Clinical Oncology: Cancer Clinical Trials 2004, 27:477-480.